首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1459635

全球糖尿病前期市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Prediabetes Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年03月01日 | 出版商:

Value Market Research | 英文 134 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球糖尿病前期市场需求预计将从 2023 年的 2.024 亿美元增至 2032 年的近 4.1208 亿美元，2024-2032 年研究期间复合CAGR为 8.22%。

糖尿病前期是一种健康状况，其特征是血糖水平高于正常水平，但不足以归类为第 2 型糖尿病。如果不及时治疗，糖尿病前期患者罹患糖尿病、心臟病和中风的风险更高。规律运动、营养饮食习惯和体重管理等生活方式的改变有助于延缓或预防第 2 型糖尿病的进展。定期监测血糖值和筛检其他危险因子对于早期发现和介入至关重要。

市场动态

糖尿病前期市场受到多种因素的影响，包括糖尿病前期盛行率的上升、糖尿病预防意识的增强以及促进早期介入和生活方式改变的措施。糖尿病前期是糖尿病和心血管疾病发生的重要危险因子。随着全球糖尿病负担达到流行病的程度，人们越来越认识到糖尿病前期是一个重要的公共卫生问题，这推动了识别高风险族群并实施预防措施的努力。此外，宣传活动、社区为基础的糖尿病预防计划和工作场所健康措施提高了公众对健康生活方式选择在预防糖尿病和减轻疾病负担方面重要性的认识。此外，诊断技术和风险评估工具的进步使医疗保健提供者能够及早识别糖尿病前期患者并实施个人化干预措施以减缓疾病进展。此外，医疗保健组织、政府机构和非营利组织之间的合作支持实施针对糖尿病前期危险因子（例如肥胖、久坐生活方式和不健康饮食）的循证干预措施。然而，生活方式的改变导致糖尿病前期盛行率增加、医疗保健成本上升以及获得预防性护理服务的机会有限，可能会阻碍市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球糖尿病前期市场的各个细分市场进行了包容性评估。糖尿病前期产业的成长和趋势为本研究提供了整体方法。

市场区隔

糖尿病前期市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按药物类别

双胍
噻唑烷二酮类
胰高血糖素样胜肽-1 激动剂 (GLP-1)
SGLT2 抑制剂
DPP-4 抑制剂
其他的

按年龄段

儿童（12-18 岁）
成人（18-49）
老年人（50岁以上）

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲糖尿病前期市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。糖尿病前期市场的主要参与者包括诺和诺德、Valbiotis、Resverlogix、Caelus Health、SciMar、Boston Therapeutics、Aphaia Pharma、阿斯特捷利康、百时美施贵宝。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：糖尿病前期公司的竞争格局

糖尿病前期市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
Novo Nordisk

公司简介
公司收入
产品
最近的发展

Valbiotis

公司简介
公司收入
产品
最近的发展

Resverlogix

公司简介
公司收入
产品
最近的发展

Caelus Health

公司简介
公司收入
产品
最近的发展

SciMar

公司简介
公司收入
产品
最近的发展

Boston Therapeutics

公司简介
公司收入
产品
最近的发展

Aphaia Pharma

公司简介
公司收入
产品
最近的发展

AstraZeneca

公司简介
公司收入
产品
最近的发展

Bristol-Myers Squibb

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112114025

The global demand for Prediabetes Market is presumed to reach the market size of nearly USD 412.08 Million by 2032 from USD 202.4 Million in 2023 with a CAGR of 8.22% under the study period 2024 - 2032.

Prediabetes is a health condition featured by elevated blood sugar levels that exceed usual but are not great enough to be classified as type 2 diabetes. Individuals with prediabetes are at a higher risk of developing diabetes, heart disease, & stroke if left untreated. Lifestyle modifications such as regular exercise, nutritious dietary habits, and weight management can help delay or prevent the progression of type 2 diabetes. Regular monitoring of blood sugar levels and screening for other risk factors are crucial for early detection and intervention.

MARKET DYNAMICS

The prediabetes market is influenced by several factors, including the rising prevalence of prediabetes, increasing awareness about diabetes prevention, and initiatives promoting early intervention and lifestyle modifications. Prediabetes poses a significant risk factor for the development of diabetes and cardiovascular diseases. With the global burden of diabetes reaching epidemic proportions, there is growing recognition of prediabetes as a critical public health concern, driving efforts to identify at-risk individuals and implement preventive measures. Moreover, awareness campaigns, community-based diabetes prevention programs, and workplace wellness initiatives raise public awareness about the importance of healthy lifestyle choices in preventing diabetes and reducing disease burden. Additionally, advancements in diagnostic technologies and risk assessment tools enable healthcare providers to identify individuals with prediabetes early and implement personalized interventions to mitigate disease progression. Furthermore, collaborations between healthcare organizations, government agencies, and non-profit organizations support the implementation of evidence-based interventions targeting prediabetes risk factors, such as obesity, sedentary lifestyle, and unhealthy diet. However, lifestyle changes leading to increased prevalence of prediabetes, rising healthcare costs, and limited access to preventive care services may impede market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of prediabetes. The growth and trends of prediabetes industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the prediabetes market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Diguanide
Thiazolidinediones
Glucagon-Like Peptide-1 Agonists (GLP-1)
SGLT2 Inhibitors
DPP-4 Inhibitors
Others

By Age Group

Children (12-18 Years)
Adults (18-49)
Elderly (50+)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Prediabetes market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Prediabetes market include Novo Nordisk, Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, Aphaia Pharma, AstraZeneca, Bristol-Myers Squibb. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PREDIABETES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Age Group
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PREDIABETES MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Diguanide Historic and Forecast Sales by Regions
5.5 Thiazolidinediones Historic and Forecast Sales by Regions
5.6 Glucagon-Like Peptide-1 Agonists (GLP-1) Historic and Forecast Sales by Regions
5.7 SGLT2 Inhibitors Historic and Forecast Sales by Regions
5.8 DPP-4 Inhibitors Historic and Forecast Sales by Regions
5.9 Others Historic and Forecast Sales by Regions

6 . GLOBAL PREDIABETES MARKET ANALYSIS BY AGE GROUP

6.1 Overview by Age Group
6.2 Historical and Forecast Data
6.3 Analysis by Age Group
6.4 Children (12-18 Years) Historic and Forecast Sales by Regions
6.5 Adults (18-49) Historic and Forecast Sales by Regions
6.6 Elderly (50+) Historic and Forecast Sales by Regions

7 . GLOBAL PREDIABETES MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PREDIABETES COMPANIES

8.1. Prediabetes Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF PREDIABETES INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Novo Nordisk
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Valbiotis
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Resverlogix
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Caelus Health
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. SciMar
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Boston Therapeutics
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Aphaia Pharma
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. AstraZeneca
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Bristol-Myers Squibb
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments